Les publications les plus récentes
Boucher L, Rozalska L, Sorel N, Olivier G, Hernanz MPG, Cayssials E, Raimbault A, Chomel JC. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation. Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439.
​
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Luque Paz D, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. Am J Hematol. 2023 Jun;98(6):922-931. doi: 10.1002/ajh.26917.
PRODUCTION SCIENTIFIQUE
_______________________________________________2024_______________________________________________
​
Boucher L, Rozalska L, Sorel N, Olivier G, Hernanz MPG, Cayssials E, Raimbault A, Chomel JC. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation. Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439.
​
_______________________________________________2023_______________________________________________
​
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Luque Paz D, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. Am J Hematol. 2023 Jun;98(6):922-931. doi: 10.1002/ajh.26917.
​
Chabrun F, Lacombe V, Dieu X, Geneviève F, Urbanski G. Accurate stratification between VEXAS syndrome and differential diagnoses by deep learning analysis of peripheral blood smears. Clin Chem Lab Med. 2023 Feb 2. doi: 10.1515/cclm-2022-1283.
​
Declerck C, Giltat A, Boutemy R, Brisset-Dheilly M, Pelhatre A, Hunault-Berger M, Kempf M, Kouatchet A, Mahieu R, Tanguy-Schmidt A, Orvain C. Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation. Leuk Lymphoma. 2023 Jun;64(6):1204-1207. doi: 10.1080/10428194.2023.2196595.
​
Desprez C, Kouatchet A, Marchand T, Mear JB, Tadié JM, Peterlin P, Chevalier P, Canet E, Couturier MA, Guillerm G, Bodenes L, Gyan E, Villate A, Ehrmann S, Lebreton A, Lester MA, Fronteau C, Larhantec G, André V, Riou J, Hunault-Berger M, Schmidt-Tanguy A, Orvain C. Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study. Ann Hematol. 2023 Jun;102(6):1383-1393. doi: 10.1007/s00277-023-05205-6.
_______________________________________________2022 ________________________________________________
​
Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417. https://doi.org/10.1038/s41375-022-01677-z
​
Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., Abbara, C., 2022. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 14, 792. https://doi.org/10.3390/pharmaceutics14040792
​
Dulucq, S., Nicolini, F.E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J.-C., Gardembas, M., Turlure, P., Dubruille, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., Joly, B., Henni, T., Cayssials, E., Zunic, P., Berger, M.G., Villemagne, B., Robbesyn, F., Morisset, S., Mahon, F.-X., Etienne, G., 2022. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. haematol 107, 2859–2869. https://doi.org/10.3324/haematol.2022.280811
​
Gyan, E., Pigneux, A., Hunault, M., Peterlin, P., Carré, M., Bay, J.-O., Bonmati, C., Gallego-Hernanz, M.-P., Lioure, B., Bertrand, P., Vallet, N., Ternant, D., Darrouzain, F., Picou, F., Béné, M.-C., Récher, C., Hérault, O., 2022. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Sci Rep 12, 9748. https://doi.org/10.1038/s41598-022-13626-y
​
Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6. https://doi.org/10.1186/s40164-022-00262-5
​
Lemoine, S., Mornet, C., Quintin-Roue, I., Rousselet, M.-C., Cottin, L., Georgeais, A., Dubouis, L., Boyer, F., Orvain, C., Caillon, C., Renard, M., Le Brun, V., Le Clech, L., Ianotto, J.-C., Génin, E., Burroni, B., Ugo, V., Paz, D.L., Lippert, E., 2022. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. haematol 107, 2725–2731. https://doi.org/10.3324/haematol.2022.280917
​
Roux, B., Picou, F., Debeissat, C., Koubi, M., Gallay, N., Hirsch, P., Ravalet, N., Béné, M.C., Maigre, M., Hunault, M., Mosser, J., Etcheverry, A., Gyan, E., Delhommeau, F., Domenech, J., Herault, O., 2022. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 29, 1263–1275. https://doi.org/10.1038/s41417-022-00441-w
​
Sureau, L., Buors, C., Ianotto, J.-C., Boyer, F., Tanguy-Schmidt, A., Roy, L., Cayssials, E., Cailly, L., Chomel, J.-C., Chauveau, A., Orvain, C., Mansier, O., Ranta, D., Robles, M., Gyan, E., Hérault, O., Nimubona, S., Marchand, T., Lippert, E., Riou, J., Ugo, V., Luque Paz, D., 2022. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes. Blood Cancer J. 12, 56. https://doi.org/10.1038/s41408-022-00646-0